Literature DB >> 8447699

Rheumatic disease following immunotherapy.

C Scheibenbogen, U Keilholz, A Pezzutto, W Hunstein.   

Abstract

Entities:  

Mesh：

Year:  1993        PMID： 8447699      PMCID： PMC1005000          DOI： 10.1136/ard.52.2.165-a

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Rheumatoid arthritis-like disease after alpha-interferon therapy.

Authors:  P Chazerain; O Meyer; M F Kahn
Journal:  Ann Intern Med       Date:  1992-03-01       Impact factor: 25.391

2.  Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.

Authors:  L E Rönnblom; G V Alm; K E Oberg
Journal:  Ann Intern Med       Date:  1991-08-01       Impact factor: 25.391

3.  Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma.

Authors:  S Scalzo; A Gengaro; G Boccoli; R Masciulli; G Giannella; G Salvo; P Marolla; P Carlini; G Massimini; E E Holdener
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

4.  Regional administration of lymphokine-activated killer cells can be superior to intravenous application.

Authors:  U Keilholz; P Schlag; W Tilgen; B Brado; F Galm; J Görich; G W Kauffmann; P Möller; S Schneider; W Hunstein
Journal:  Cancer       Date:  1992-04-15       Impact factor: 6.860

5.  Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

Authors:  K C Conlon; W J Urba; J W Smith; R G Steis; D L Longo; J W Clark
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

6.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

7.  Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

Authors:  M B Atkins; J W Mier; D R Parkinson; J A Gould; E M Berkman; M M Kaplan
Journal:  N Engl J Med       Date:  1988-06-16       Impact factor: 91.245

8.  Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

Authors:  S A Rosenberg; M T Lotze; J C Yang; W M Linehan; C Seipp; S Calabro; S E Karp; R M Sherry; S Steinberg; D E White
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544
  8 in total
  2 in total

Review 1.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 2.  Paraneoplastic rheumatic syndromes.

Authors:  H J Mitnick
Journal:  Curr Rheumatol Rep       Date:  2000-04       Impact factor: 4.686
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.